- Home
- BZUN vs PLX Comparison
BZUN vs PLX Comparison
Compare BZUN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- PLX
- Stock Information
- Founded
- BZUN 2007
- PLX 1993
- Country
- BZUN China
- PLX United States
- Employees
- BZUN N/A
- PLX N/A
- Industry
- BZUN Catalog/Specialty Distribution
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BZUN Consumer Discretionary
- PLX Health Care
- Exchange
- BZUN Nasdaq
- PLX Nasdaq
- Market Cap
- BZUN 144.4M
- PLX 127.4M
- IPO Year
- BZUN N/A
- PLX 1998
- Fundamental
- Price
- BZUN $3.39
- PLX $1.55
- Analyst Decision
- BZUN Buy
- PLX Strong Buy
- Analyst Count
- BZUN 2
- PLX 1
- Target Price
- BZUN $3.20
- PLX $15.00
- AVG Volume (30 Days)
- BZUN 231.4K
- PLX 573.2K
- Earning Date
- BZUN 08-28-2025
- PLX 08-14-2025
- Dividend Yield
- BZUN N/A
- PLX N/A
- EPS Growth
- BZUN N/A
- PLX N/A
- EPS
- BZUN N/A
- PLX 0.08
- Revenue
- BZUN $1,349,630,922.00
- PLX $61,948,000.00
- Revenue This Year
- BZUN $5.27
- PLX $14.53
- Revenue Next Year
- BZUN $3.46
- PLX $75.77
- P/E Ratio
- BZUN N/A
- PLX $20.02
- Revenue Growth
- BZUN 7.73
- PLX 62.79
- 52 Week Low
- BZUN $2.12
- PLX $0.90
- 52 Week High
- BZUN $4.38
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- BZUN 70.15
- PLX 47.97
- Support Level
- BZUN $2.72
- PLX $1.47
- Resistance Level
- BZUN $3.15
- PLX $1.57
- Average True Range (ATR)
- BZUN 0.15
- PLX 0.07
- MACD
- BZUN 0.05
- PLX -0.00
- Stochastic Oscillator
- BZUN 100.00
- PLX 31.82
About BZUN Baozun Inc.
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.